• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在病毒学失败期间对1型人类免疫缺陷病毒的拉替拉韦敏感性和整合酶复制能力的纵向分析。

Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure.

作者信息

Fransen Signe, Karmochkine Marina, Huang Wei, Weiss Laurence, Petropoulos Christos J, Charpentier Charlotte

机构信息

Monogram Biosciences, South San Francisco, California, USA.

出版信息

Antimicrob Agents Chemother. 2009 Oct;53(10):4522-4. doi: 10.1128/AAC.00651-09. Epub 2009 Aug 10.

DOI:10.1128/AAC.00651-09
PMID:19667293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2764161/
Abstract

We characterized the raltegravir (RAL) susceptibility and the integrase (IN)-mediated replication capacity (RC) of RAL-resistant human immunodeficiency virus type 1 from two patients experiencing virologic failure during continuous RAL salvage therapy. The following two distinct outcomes were observed: (i) the selective outgrowth of virus with high-level RAL resistance and high IN-mediated RC leading to significant viral load rebound and (ii) the selection of virus with a slight reduction in RAL susceptibility and low IN-mediated RC resulting in sustained low-level viremia.

摘要

我们对两名在持续的雷特格韦挽救治疗期间出现病毒学失败的患者的1型人类免疫缺陷病毒的雷特格韦（RAL）敏感性和整合酶（IN）介导的复制能力（RC）进行了表征。观察到以下两种不同的结果：（i）具有高水平RAL耐药性和高IN介导的RC的病毒选择性生长，导致病毒载量显著反弹；（ii）选择了RAL敏感性略有降低且IN介导的RC较低的病毒，导致持续的低水平病毒血症。

相似文献

1
Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure.在病毒学失败期间对1型人类免疫缺陷病毒的拉替拉韦敏感性和整合酶复制能力的纵向分析。
Antimicrob Agents Chemother. 2009 Oct;53(10):4522-4. doi: 10.1128/AAC.00651-09. Epub 2009 Aug 10.
2
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.携带可导致非核苷类逆转录酶和整合酶链转移抑制剂耐药突变的 HIV-1 中病毒适应性和药物敏感性的改变。
J Virol. 2014 Aug;88(16):9268-76. doi: 10.1128/JVI.00695-14. Epub 2014 Jun 4.
3
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.对拉替拉韦的耐药性突出了整合酶 148 密码子的突变，从而赋予了对第二代 HIV-1 整合酶抑制剂的交叉耐药性。
Antiviral Res. 2011 Aug;91(2):167-76. doi: 10.1016/j.antiviral.2011.05.011. Epub 2011 Jun 12.
4
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.1型人类免疫缺陷病毒对拉替拉韦的敏感性丧失是通过多种不重叠的遗传途径造成的。
J Virol. 2009 Nov;83(22):11440-6. doi: 10.1128/JVI.01168-09. Epub 2009 Sep 16.
5
MK-0536 inhibits HIV-1 integrases resistant to raltegravir.MK-0536 抑制对拉替拉韦耐药的 HIV-1 整合酶。
Antimicrob Agents Chemother. 2011 Nov;55(11):5127-33. doi: 10.1128/AAC.05288-11. Epub 2011 Aug 29.
6
Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.基于拉替拉韦的治疗方案失败的大量治疗患者中整合酶 N155H 变异的纵向分析。
HIV Med. 2013 Feb;14(2):85-91. doi: 10.1111/j.1468-1293.2012.01039.x. Epub 2012 Sep 20.
7
Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.Y143 艾滋病毒 1 整合酶突变对拉替拉韦体外和体内耐药性的影响。
Antimicrob Agents Chemother. 2010 Jan;54(1):491-501. doi: 10.1128/AAC.01075-09. Epub 2009 Nov 9.
8
The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.HIV-1整合酶中R263K和T66I耐药性替代的组合与高水平病毒复制及高水平耐药性的发展不相容。
J Virol. 2015 Nov;89(22):11269-74. doi: 10.1128/JVI.01881-15. Epub 2015 Aug 26.
9
Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.抗雷特格韦的 HIV-1 整合酶柔性环突变体的生化和药理学分析。
Biochemistry. 2010 May 4;49(17):3715-22. doi: 10.1021/bi100130f.
10
Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.HIV-1 整合酶中的拉替拉韦耐药突变对病毒适应性的影响。
J Acquir Immune Defic Syndr. 2010 Oct;55(2):148-55. doi: 10.1097/QAI.0b013e3181e9a87a.

引用本文的文献

1
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.在 DAWNING 研究中，接受多拉韦林联合两种核苷类逆转录酶抑制剂治疗的、有抗逆转录病毒治疗史、整合酶抑制剂初治的 HIV-1 感染的成年患者中，整合酶抑制剂耐药机制和结构特征。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164321. doi: 10.1128/AAC.01643-21. Epub 2021 Oct 25.
2
Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.整合酶链转移抑制剂是有效的抗 HIV 药物。
Viruses. 2021 Jan 29;13(2):205. doi: 10.3390/v13020205.
3
Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence.雷特格韦诱导的HIV-1整合酶适应性：结构、变异性及共突变分析
Front Microbiol. 2019 Sep 3;10:1981. doi: 10.3389/fmicb.2019.01981. eCollection 2019.
4
Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.单用度鲁特韦或拉替拉韦均不能持久抑制人源化小鼠的 HIV 病毒血症。
J Antimicrob Chemother. 2017 Sep 1;72(9):2570-2573. doi: 10.1093/jac/dkx195.
5
HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.HIV-2整合酶多态性及对含raltegravir方案治疗失败的HIV-2感染患者的纵向基因分型分析
PLoS One. 2014 Mar 28;9(3):e92747. doi: 10.1371/journal.pone.0092747. eCollection 2014.
6
The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.抗病毒药物耐药性出现后开发新型HIV-1逆转录酶和整合酶抑制剂的必要性
Scientifica (Cairo). 2012;2012:238278. doi: 10.6064/2012/238278. Epub 2012 Dec 31.
7
Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.整合酶编码区以外的耐药突变会影响人类免疫缺陷病毒的复制适应性，但不影响其对整合酶链转移抑制剂的敏感性。
PLoS One. 2013 Jun 11;8(6):e65631. doi: 10.1371/journal.pone.0065631. Print 2013.
8
HIV Drug Resistance and the Advent of Integrase Inhibitors.HIV 耐药性与整合酶抑制剂的出现。
Curr Infect Dis Rep. 2013 Feb;15(1):85-100. doi: 10.1007/s11908-012-0305-1.
9
Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.HIV-1 整合酶 143、148 和 155 位氨基酸的替换在体内定义了对拉替拉韦耐药的不同遗传屏障。
J Virol. 2012 Jul;86(13):7249-55. doi: 10.1128/JVI.06618-11. Epub 2012 May 2.
10
Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.拉替拉韦用于HIV-1感染：初治患者的安全性和疗效
Clin Med Rev Ther. 2011 Dec 20;2012(4):13-30. doi: 10.4137/CMRT.S5022.

本文引用的文献

1
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.HIV-1感染患者对拉替拉韦产生耐药性过程中的准种变异动态。
J Antimicrob Chemother. 2009 Apr;63(4):795-804. doi: 10.1093/jac/dkp014. Epub 2009 Feb 16.
2
Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.接受雷特格韦挽救治疗失败的患者中HIV整合酶基因的耐药谱。
HIV Med. 2008 Oct;9(9):765-70. doi: 10.1111/j.1468-1293.2008.00628.x. Epub 2008 Jul 21.
3
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.雷特格韦用于耐药HIV-1感染的亚组分析和耐药性分析。
N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.
4
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.一种针对1型人类免疫缺陷病毒的新型表型药物敏感性检测方法。
Antimicrob Agents Chemother. 2000 Apr;44(4):920-8. doi: 10.1128/AAC.44.4.920-928.2000.